FDA
-
-
-
-
-
-
-
U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer wit
-
-
-
-
-
-
-
Morgan Stanley Upgrades Roche Holding (ROG:SW) (RHHBY) to Equalweight
-
-
-
-
-
-
-
Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories
-
-
-
-
-
-
-
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
-
-
-
-
-
-
-
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
-
-
-
-
-
-
-
FDA approves Genentech's Gazyva for lupus nephritis treatment
-
-
-
-
-
-
-
FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
-
324,435 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

